ArticleNature immunology2024
Cutaneous T cell lymphoma atlas reveals malignant T
Erratum issuedAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Cutaneous T Cell Lymphoma: Targeting the Survival Network in Mycosis Fungoides and Sézary Syndrome.Cancers · 2026Review
- Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
- Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- Review
- Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy.Cancers · 2026Article
- TCRVβ-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.Blood advances · 2026Article
- Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma.Allergy · 2026Article
- IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.Journal for immunotherapy of cancer · 2026Article
- Cancer-associated fibroblasts and tertiary lymphoid structure orchestrate the spatial architecture of tumor immunity.Journal of hematology & oncology · 2026Review
- Article
- Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.American journal of clinical dermatology · 2026Review
- Review
- A Conversational Artificial Intelligence Framework for Comparative Pathway-Level Profiling of Sézary Syndrome and Primary Cutaneous CD8medRxiv : the preprint server for health sciences · 2026Article
- Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions.Experimental dermatology · 2026Article
- Conversational Artificial Intelligence-Enabled Molecular Characterization of Sézary Syndrome Reveals Distinct Pathway-Level Alterations Compared with Non-Sézary Cutaneous T-Cell Lymphoma.medRxiv : the preprint server for health sciences · 2026Article
- Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.Cell genomics · 2026Article
- Cellular interaction of mycosis fungoides tumor cells changes from cytotoxic CD8+ T cells in plaques to B cells in tumors.Frontiers in immunology · 2026Article
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- Spatiotemporal decoding of skin biology: development, aging, disease, and regeneration.Burns & trauma · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
56 authors.
Ruoyan Li *Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. rli11@mdanderson.org.ORCID http://orcid.org/0000-0001-5337-9729
Johanna Strobl *Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0003-3606-2185
Elizabeth F M Poyner *Biosciences Institute, Newcastle University, Newcastle, UK.
Aya Balbaa *Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Fereshteh TorabiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0009-0008-8660-3350
Pavel V MazinWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Nana-Jane ChipampeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-8802-0473
Emily StephensonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Ciro Ramírez-SuástegiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Vijaya Baskar Mahalingam ShanmugiahWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Louis GardnerBiosciences Institute, Newcastle University, Newcastle, UK.
Bayanne OlabiBiosciences Institute, Newcastle University, Newcastle, UK.
Rowen CoulthardNovoPath, Department of Cellular Pathology, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Rachel A BottingWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Nina ZilaDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-1193-1014
Elena PrigmoreWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Nusayhah H GopeeBiosciences Institute, Newcastle University, Newcastle, UK.ORCID http://orcid.org/0000-0001-8507-5682
Marta A ChroscikWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0009-0000-1356-4786
Efpraxia KritikakiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Justin EngelbertWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Issac GohWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Hon Man ChanWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Harriet F JohnsonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0003-0075-5297
Jasmine EllisWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0009-0008-0857-7003
Victoria RoweWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Win TunWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Gary ReynoldsBiosciences Institute, Newcastle University, Newcastle, UK.ORCID http://orcid.org/0000-0002-8142-8708
Dexin YangDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
April Rose FosterWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-5397-4365
Laure GambardellaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Elena WinheimWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-0364-662X
Chloe AdmaneWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Benjamin RumneyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Lloyd SteeleWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Laura JardineBiosciences Institute, Newcastle University, Newcastle, UK.
Julia NenonenDivision of Dermatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Keir PickardBiosciences Institute, Newcastle University, Newcastle, UK.ORCID http://orcid.org/0000-0001-6965-3817
Jennifer LumleyTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Philip HamptonDepartment of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle, Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Simeng HuBiomedical Pioneering Innovation Center and School of Life Sciences, Peking University, Beijing, China.
Fengjie LiuDepartment of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
Xiangjun LiuDepartment of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
David HorsfallWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-8086-812X
Daniela Basurto-LozadaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0003-3943-8424
Louise GrimbleBiosciences Institute, Newcastle University, Newcastle, UK.
Chris M BaconWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Sophie C WeatherheadDepartment of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle, Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-8705-8867
Hanna BraunerDivision of Dermatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Yang WangDepartment of Dermatology and Venerology, Peking University First Hospital, Beijing, China.ORCID http://orcid.org/0000-0001-7805-2861
Fan BaiBiomedical Pioneering Innovation Center and School of Life Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0000-0001-6119-8936
Nick J ReynoldsDepartment of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle, Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-6484-825X
Judith E AllenLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-3829-066X
Constanze JonakDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-2347-436X
Patrick M BrunnerDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sarah A TeichmannWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. st9@sanger.ac.uk.ORCID http://orcid.org/0000-0002-6294-6366
Muzlifah HaniffaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. mh32@sanger.ac.uk.ORCID http://orcid.org/0000-0002-3927-2084
Funding
Wellcome Trust
Abstract
Cutaneous T cell lymphoma (CTCL) is a potentially fatal clonal malignancy of T cells primarily affecting the skin. The most common form of CTCL, mycosis fungoides, can be difficult to diagnose, resulting in treatment delay. We performed single-cell and spatial transcriptomics analysis of skin from patients with mycosis fungoides-type CTCL and an integrated comparative analysis with human skin cell atlas datasets from healthy and inflamed skin. We revealed the co-optation of T helper 2 (T
Indexed as
B-LymphocytesLymphoma, T-Cell, CutaneousSkin NeoplasmsTh2 CellsTumor MicroenvironmentDendritic CellsFibroblastsGene Expression Regulation, NeoplasticHumansSingle-Cell AnalysisSkinTranscriptome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.